OTCMKTS:CTYX

Curative Biotechnology Competitors

$0.12
-0.02 (-14.13 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.12
Now: $0.12
$0.15
50-Day Range
$0.15
MA: $0.16
$0.19
52-Week Range
$0.00
Now: $0.12
$0.22
Volume3.62 million shs
Average Volume3.04 million shs
Market Capitalization$47.20 million
P/E RatioN/A
Dividend YieldN/A
Beta-31.94

Competitors

Curative Biotechnology (OTCMKTS:CTYX) Vs. CLBS, BXRX, CCEL, GRNV, EMMA, and PFHOD

Should you be buying CTYX stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to Curative Biotechnology, including Caladrius Biosciences (CLBS), Baudax Bio (BXRX), Cryo-Cell International (CCEL), GreenVision Acquisition (GRNV), Emmaus Life Sciences (EMMA), and Pacific Health Care Organization (PFHOD).

Caladrius Biosciences (NASDAQ:CLBS) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Institutional and Insider Ownership

9.0% of Caladrius Biosciences shares are owned by institutional investors. 10.3% of Caladrius Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Caladrius Biosciences has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, indicating that its stock price is 3,294% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Caladrius Biosciences and Curative Biotechnology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Caladrius Biosciences01302.75
Curative Biotechnology0000N/A

Caladrius Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 553.59%. Given Caladrius Biosciences' higher probable upside, research analysts clearly believe Caladrius Biosciences is more favorable than Curative Biotechnology.

Profitability

This table compares Caladrius Biosciences and Curative Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Caladrius BiosciencesN/A-68.33%-57.61%
Curative BiotechnologyN/AN/AN/A

Earnings and Valuation

This table compares Caladrius Biosciences and Curative Biotechnology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caladrius BiosciencesN/AN/A$-19,360,000.00($1.88)-0.81
Curative BiotechnologyN/AN/AN/AN/AN/A

Summary

Caladrius Biosciences beats Curative Biotechnology on 5 of the 7 factors compared between the two stocks.

Baudax Bio (NASDAQ:BXRX) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Insider & Institutional Ownership

7.9% of Baudax Bio shares are owned by institutional investors. 13.1% of Baudax Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Baudax Bio and Curative Biotechnology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baudax BioN/AN/A$-32,560,000.00($3.48)-0.31
Curative BiotechnologyN/AN/AN/AN/AN/A

Volatility & Risk

Baudax Bio has a beta of 2.56, suggesting that its share price is 156% more volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, suggesting that its share price is 3,294% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Baudax Bio and Curative Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Baudax Bio00203.00
Curative Biotechnology0000N/A

Baudax Bio presently has a consensus target price of $13.50, suggesting a potential upside of 1,161.68%. Given Baudax Bio's higher possible upside, research analysts clearly believe Baudax Bio is more favorable than Curative Biotechnology.

Profitability

This table compares Baudax Bio and Curative Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Baudax BioN/AN/AN/A
Curative BiotechnologyN/AN/AN/A

Summary

Baudax Bio beats Curative Biotechnology on 5 of the 5 factors compared between the two stocks.

Curative Biotechnology (OTCMKTS:CTYX) and Cryo-Cell International (OTCMKTS:CCEL) are both small-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Curative Biotechnology and Cryo-Cell International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Curative Biotechnology0000N/A
Cryo-Cell International0000N/A

Institutional & Insider Ownership

1.0% of Cryo-Cell International shares are owned by institutional investors. 53.8% of Cryo-Cell International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Curative Biotechnology and Cryo-Cell International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Curative BiotechnologyN/AN/AN/A
Cryo-Cell International10.39%-58.74%7.30%

Volatility and Risk

Curative Biotechnology has a beta of -31.94, meaning that its share price is 3,294% less volatile than the S&P 500. Comparatively, Cryo-Cell International has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.

Valuation & Earnings

This table compares Curative Biotechnology and Cryo-Cell International's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curative BiotechnologyN/AN/AN/AN/AN/A
Cryo-Cell International$31.80 million2.35$2.29 millionN/AN/A

Cryo-Cell International has higher revenue and earnings than Curative Biotechnology.

Summary

Cryo-Cell International beats Curative Biotechnology on 6 of the 7 factors compared between the two stocks.

Curative Biotechnology (OTCMKTS:CTYX) and GreenVision Acquisition (NASDAQ:GRNV) are both small-cap business services companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Profitability

This table compares Curative Biotechnology and GreenVision Acquisition's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Curative BiotechnologyN/AN/AN/A
GreenVision AcquisitionN/AN/AN/A

Valuation and Earnings

This table compares Curative Biotechnology and GreenVision Acquisition's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curative BiotechnologyN/AN/AN/AN/AN/A
GreenVision AcquisitionN/AN/AN/AN/AN/A

Insider and Institutional Ownership

67.7% of GreenVision Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Curative Biotechnology and GreenVision Acquisition, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Curative Biotechnology0000N/A
GreenVision Acquisition0000N/A

Summary

GreenVision Acquisition beats Curative Biotechnology on 1 of the 1 factors compared between the two stocks.

Emmaus Life Sciences (OTCMKTS:EMMA) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Emmaus Life Sciences and Curative Biotechnology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emmaus Life Sciences0000N/A
Curative Biotechnology0000N/A

Valuation & Earnings

This table compares Emmaus Life Sciences and Curative Biotechnology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emmaus Life Sciences$1.32 million48.24$-2,370,000.00N/AN/A
Curative BiotechnologyN/AN/AN/AN/AN/A

Curative Biotechnology has lower revenue, but higher earnings than Emmaus Life Sciences.

Insider and Institutional Ownership

0.1% of Emmaus Life Sciences shares are held by institutional investors. 36.9% of Emmaus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Emmaus Life Sciences has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, indicating that its stock price is 3,294% less volatile than the S&P 500.

Profitability

This table compares Emmaus Life Sciences and Curative Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emmaus Life SciencesN/AN/AN/A
Curative BiotechnologyN/AN/AN/A

Summary

Emmaus Life Sciences beats Curative Biotechnology on 4 of the 4 factors compared between the two stocks.

Pacific Health Care Organization (OTCMKTS:PFHOD) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Profitability

This table compares Pacific Health Care Organization and Curative Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Health Care Organization16.87%14.47%12.96%
Curative BiotechnologyN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Pacific Health Care Organization and Curative Biotechnology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Health Care Organization0000N/A
Curative Biotechnology0000N/A

Earnings & Valuation

This table compares Pacific Health Care Organization and Curative Biotechnology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Health Care Organization$6.80 million2.35$1.36 millionN/AN/A
Curative BiotechnologyN/AN/AN/AN/AN/A

Pacific Health Care Organization has higher revenue and earnings than Curative Biotechnology.

Risk & Volatility

Pacific Health Care Organization has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, indicating that its stock price is 3,294% less volatile than the S&P 500.

Summary

Pacific Health Care Organization beats Curative Biotechnology on 5 of the 5 factors compared between the two stocks.


Curative Biotechnology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
1.5$1.53-1.3%$91.03 millionN/A-2.39Decrease in Short Interest
Baudax Bio logo
BXRX
Baudax Bio
1.4$1.07-0.9%$75.05 millionN/A-0.31Analyst Upgrade
Increase in Short Interest
News Coverage
Cryo-Cell International logo
CCEL
Cryo-Cell International
0.9$9.88-2.1%$74.80 million$31.80 million24.70High Trading Volume
GRNV
GreenVision Acquisition
0.3$10.18-0.1%$73.17 millionN/A0.00Increase in Short Interest
Emmaus Life Sciences logo
EMMA
Emmaus Life Sciences
0.2$1.30-0.0%$63.68 million$1.32 million0.00News Coverage
PFHOD
Pacific Health Care Organization
0.5$1.25-228.0%$52.48 million$6.80 million0.00Gap Up
BRTXQ
BioRestorative Therapies
0.0$0.01-0.0%$16.56 million$110,000.00-0.01Gap Down
BioRestorative Therapies logo
BRTX
BioRestorative Therapies
0.6$0.01-0.0%$16.56 million$110,000.000.00Decrease in Short Interest
Gap Down
PFHO
Pacific Health Care Organization
0.8$1.12-2.7%$14.27 million$7.33 million0.00
GNOW
American Caresource
0.7$0.01-0.0%$124,000.00N/A0.00Gap Down
HYBE
Hybrid Energy
0.0$0.00-0.0%$0.00N/A0.00Increase in Short Interest
News Coverage
QMED
QMed
0.2$0.00-0.0%$0.00N/A0.00
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.